BioMarin Announces FDA Approval for VIMIZIM(TM) (elosulfase alfa) for the Treatment of Patients With Morquio A Syndrome

[GlobeNewswire] – SAN RAFAEL, Calif. — BioMarin Pharmaceutical Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved VIMIZIM(TM) (elosulfase alfa) for patients with Mucopolysaccharidosis type … more

View todays social media effects on BMRN

View the latest stocks trending across Twitter. Click to view dashboard

See who BioMarin is hiring next, click here to view